US2011059125A1PendingUtilityA1
Zwitterionic immunomodulators for the treatment of asthma and allergy
Est. expiryMar 31, 2023(expired)· nominal 20-yr term from priority
A61P 37/00A61P 37/08A61K 35/744A61K 45/06A61K 31/715A61K 9/0075A61K 31/726A61K 38/164A61K 2039/55583A61P 11/06A61K 39/35Y02A50/30
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.
Claims
exact text as granted — not AI-modifiedWe claim:
1 - 66 . (canceled)
67 . A method for inhibiting an antigen-specific immune response in a subject, wherein the antigen-specific response is other than an allergic condition or asthma, comprising administering to a subject in need of inhibition of an antigen-specific response, other than an allergic condition or asthma, (a) an antigen and (b) an isolated polymer in an effective amount to inhibit in the subject an immune response to the antigen, wherein the polymer includes repeating units of a charge motif characteristic of B. fragilis polysaccharide A (PS A), the motif being a positively charged free amino moiety and a negatively charged moiety selected from the group consisting of carboxyl, phosphate, phosphonate, sulfate and sulfonate.
68 . The method of claim 67 , wherein the administering the antigen precedes the administering the polymer.
69 . The method of claim 67 , wherein the administering the antigen follows the administering the polymer.
70 . The method of claim 67 , wherein the administering the antigen and the administering the polymer are substantially contemporaneous.
71 . The method of claim 67 , wherein the administering the polymer comprises administering multiple doses of the polymer.
72 . A composition comprising a conjugate comprising an antigen and a polymer, wherein the polymer includes repeating units of a charge motif characteristic of B. fragilis polysaccharide A (PSA), the motif being a positively charged free amino moiety and a negatively charged moiety selected from the group consisting of carboxyl, phosphate, phosphonate, sulfate and sulfonate.
73 - 97 . (canceled)Join the waitlist — get patent alerts
Track US2011059125A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.